Osong Public Health Res Perspect.
2018 Apr;9(2):50-58. 10.24171/j.phrp.2018.9.2.03.
Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
- Affiliations
-
- 1Federal University of Rio de Janeiro State– UNIRIO, Brazil. lucasmedeiros.medicina@gmail.com
- 2University Center of Volta Redonda - UNIFOA, Brazil.
- 3Pontifical Catholic University of Rio de Janeiro – PUC-RJ, Brazil.
- 4Faculty of Medicine Souza Marques - FTESM, Brazil.
- KMID: 2413256
- DOI: http://doi.org/10.24171/j.phrp.2018.9.2.03
Abstract
OBJECTIVES
To evaluate the impact of 3 treatment regimens upon health-related quality of life and work productivity using patient-reported outcomes (PROs) in chronic hepatitis C infected patients: sofosbuvir (SOF) + daclatasvir (DCV); SOF + DCV + ribavirin (RBV); SOF + simeprevir (SMV).
METHODS
4 questionnaires were used to evaluate PROs before, during and after treatment: Short Form-36 (SF-36), Chronic Liver Disease Questionnaire (CLDQ) - hepatitis C virus (HCV), Work Productivity and Activity Index, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).
RESULTS
Of the global sample of 55 patients included in this study; SOF + DCV (n = 10); SOF + DCV + RBV (n = 29); SOF + SMV (n = 16) all had a statistically significant improvement in SF-36, CLDQ and FACIT-F scores during and post-treatment. No statistically significant differences in the PRO questionnaire values were observed between the distinct treatment regimens. The SOF and SMV patient groups presented higher mean PRO variations during and post-treatment, compared to the other groups: SF-36 functional capacity (16.1); SF-36 mental health (21.4); CLDQ activity (1.8); CLDQ emotional function (1.2); FACIT-F physical well-being (8.0); Total FACIT-F (21.6).
CONCLUSION
Treatment with SOF + DCV, with or without RBV, results in an improved PRO similar to treatment with SOF + SMV in chronic hepatitis C patients.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
- Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
- Comparison of Guidelines for Management of Chronic Hepatitis C
- New direct-acting antivirals for the treatment of chronic hepatitis C
- Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
